62 results about "Ganglion" patented technology

There is provided a transvenous cryoneurolysis system and method for accessing and targeting neural treatment sites to relieve a variety of clinical indications, including peripheral neuropathy. A neurosome approach is described that includes one or more target nerves to receive selective cryoneurolysis via a target vein. The system performs a variety of freeze-thaw cycles via the target vein to induce a desired axial cryolesion along a target nerve. The target nerves and veins are selected to combine the treatment of the identified neurosome for pain relief in addition to the regenerative properties of cryoneurolysis.

The invention provides an optic nerve regulation and control system based on an ultrasonic technology, a first ultrasonic module is deployed on the outer side of a target human eyelid and is provided with an Archimedes spiral type first ultrasonic array facing the human eye, and the first ultrasonic array is configured to generate a gathered ultrasonic beam which acts on a human eye retina ganglion cell area in a targeted manner; the positioning module is deployed on the outer side of a target human eyelid and is configured to measure three-dimensional geometric data when a human eyeball horizontally faces the front and measure the depth distance of a human eye retina ganglion cell area in the human eye; the optic nerve response prediction module is pre-trained with an optic nerve response prediction model facing a target human body, and the optic nerve response prediction model is configured to adjust sound intensity output of the first ultrasonic array based on stimulation feedback prediction of human eye retina ganglion cells. According to the invention, the optic nerve regulation and control system satisfies non-intrusive, high-precision and self-adaptive requirements, and has optic nerve regulation and control and repair functions.

The application provides a toxicity-enhanced neurotoxin recombinant protein and application thereof, and belongs to the technical field of biological medicine. The recombinant protein comprises a botulinum toxin type A receptor binding domain and at least one GM1 binding peptide inserted into the botulinum toxin type A receptor binding domain, and the recombinin protein can recognize and bind to ganglioside GM1. The short peptide sequence capable of binding to ganglioside GM1 is introduced into the botulinum toxin type A receptor binding domain to obtain the recombinant protein, the binding capacity of the recombinant protein to ganglioside GM1 is enhanced, the target recognition and binding capacity of the recombinant protein to the nerve cell membrane are improved, the overall affinity and endocytosis efficiency of the recombinant protein to the nerve cell are improved, and the neurotoxicity of the botulinum toxin is enhanced. The application not only improves the binding efficiency of BoNT / A in the in-vitro nerve cell model, but also shows a higher toxicity level in the functional verification, and shows a good clinical conversion prospect.

The invention discloses lower limb dyskinesia adjusting equipment and a gait adjusting method, and the equipment comprises a wearing part which comprises a housing matched with a lower limb; the projection module comprises a projector arranged on the shell, and the projection angle of the projector is adjustable; the control unit comprises a control mainboard arranged in the shell and an acquisition module communicating with the control mainboard, and the acquisition module is configured to acquire gait data of the wearing piece in real time; the projector communicates with the control mainboard, and the control mainboard is configured to control and adjust the projection angle of the projector based on the gait data acquired by the acquisition module. The lower limb dyskinesia adjusting device prompts gait disorders by using vision, and the mechanism is that the lower limb dyskinesia adjusting device can provide external sensory cues for the patient and stimulate the visual system of the patient, so that neural activity of the premotor area is activated. Visual information is used for guiding gaits, and the deficiency of internal movement rhythm caused by basal ganglion dysfunction is made up.

The present disclosure pertains to the field of animal disease models, specifically to a method for constructing an animal model of open-angle glaucoma. In this model, the pathogenesis of open-angle glaucoma is mimicked by inducing necroptosis in trabecular meshwork cells through the injection of IFN-γ into the anterior chamber. This process leads to the inhibition of trabecular meshwork activity and functional impairment, resulting in elevated intraocular pressure and subsequent optic nerve changes indicative of glaucoma. The pathophysiological alterations observed in the animal model closely resemble those seen in human open-angle glaucoma, including chamber angle opening, trabecular meshwork dysfunction, increased intraocular pressure, and loss of RGCs.

The invention discloses Hangzhou white chrysanthemum-derived exosome-like nano-vesicles, a preparation method thereof and application of the nano-vesicles in treatment of optic nerve retinal degeneration diseases. In-vitro experiments show that the Hangzhou white chrysanthemum-derived exosome-like nano-vesicles provided by the invention can effectively inhibit glutamic acid-induced retinal cell oxidative stress and mitochondrial injury and improve the cell activity. In-vivo experiments show that the survival rate of ganglion cells in the retina of an NMDA injury model mouse can be remarkably improved by injecting the Hangzhou white chrysanthemum-derived exosome-like nano-vesicle into a vitreous cavity, and the visual electrophysiological function of the NMDA injury model mouse can be improved. The invention provides a new thought and method for treatment of optic nerve retinal degeneration diseases, and has a wide application prospect. In addition, the preparation method of the Hangzhou white chrysanthemum-derived exosome-like nano-vesicle provided by the invention is simple, and has the advantages of low cost, wide applicability, good safety, no animal-derived components and the like.

The application discloses application of a peripheral nervous system Mas-related G protein-coupled receptor D as a target point in preparation of a medicine for screening for relieving opioid tolerance. Jun The application further provides a medicine composition for regulating opioid tolerance, containing a Mas-related G protein-coupled receptor D siRNA sequence shown in SEQ ID NO. 1 or a siRNA sequence shown in SEQ ID NO. 2. The application further provides an in-situ hybridization kit for detecting expression of a Mas-related G protein-coupled receptor D gene in a dorsal root ganglion tissue of a peripheral nervous system. The application expands a new path for opioid companion diagnosis and intervention.

The embodiment of the invention relates to the technical field of instrument data control, and discloses a non-invasive electrode closed-loop feedback stellate ganglion block electrical stimulation device. According to the device, a control module carries out closed-loop control processing on initial stimulation parameters and carries out adjustment processing on stimulation frequency and intensity to obtain an optimal control parameter combination; the acquisition module performs multi-dimensional acquisition processing on the physiological parameters to obtain a monitoring data set and performs threshold judgment processing to obtain a stimulation control instruction; the analysis module performs dynamic analysis processing on the monitoring data in the stimulation process to obtain a parameter adjustment strategy, and performs optimization processing on the stimulation parameters according to the parameter adjustment strategy to obtain steady-state control parameters; and the evaluation module carries out integration analysis processing on the control process data to obtain a working state evaluation index, and carries out classified statistical processing according to the evaluation index to obtain a parameter optimization suggestion. According to the invention, adaptive adjustment of the stimulation parameters and intelligent evaluation of the system operation state are realized.

The present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable vehicle and non-pungent derivatives of capsaicin, in their tautomeric forms and pharmaceutically acceptable salts, as the sole active ingredient, for use in the stimulation of the sphenopalatine ganglion and the enhancement of cerebral blood flow, to prevent or reduce brain injury resulting from decreased cerebral blood flow. The composition is administered via the oral transmucosal route, preferably in the form of a mucoadhesive tablet, and may be formulated for immediate or prolonged release, ensuring effective and tolerable absorption while avoiding the irritant effects associated with pungent capsaicin.

The invention discloses application of a peripheral nervous system Mas related G protein coupled receptor D as a target spot in preparing and screening a medicine for relieving opioid medicine tolerance. The invention also provides a pharmaceutical composition for regulating and controlling the tolerance of the opioid drugs. The pharmaceutical composition contains a Mas related G protein coupled receptor D siRNA sequence as shown in SEQ ID NO. 1 or a Jun siRNA sequence as shown in SEQ ID NO. 2. The invention also provides an in-situ hybridization kit for detecting the expression of the Mas related G protein coupled receptor D gene in the dorsal root ganglion tissue of the peripheral nervous system. According to the invention, a new path for accompanying diagnosis and intervention of opioid drugs is expanded.

The invention relates to the technical field of medical monitoring, and particularly discloses an AI anesthesia depth monitoring system combined with nerve stimulation, which is characterized in that standardized electrical stimulation is applied to a motor nerve pathway of a patient in a general anesthesia state, and spinal nerve electrical signals and limb movement signals induced by the standardized electrical stimulation are synchronously acquired and analyzed; performing time-frequency transformation on the neural signal to extract a dominant oscillation mode of the neural signal, and generating a neural rhythm disorder degree characteristic value by quantizing frequency jitter and amplitude attenuation; analyzing the time sequence collaboration of the motion signal and the stimulation and the motion form, and generating a motion response deviation characteristic value; fusing the two features into a two-dimensional feature vector, inputting the two-dimensional feature vector into a pre-trained anesthesia depth classification model, and directly outputting an objective anesthesia depth level; and finally, starting grading early warning according to the grade change trend and generating a monitoring report.

Systems, devices, and methods for treating a nerve injury in a patient are provided. A system for treating a patient includes at least one of a nerve graft-conduit or nerve cap-graft comprise a nerve segment derived from a tissue source. Methods for producing a medical device comprising a nerve segment, for obtaining an ideal degree of decellularization of a nerve segment, and for treating a patient with a medical device comprising a nerve segment are provided.

The invention belongs to the technical field of biological medicines, and discloses application of dasatinib in preparation of a medicine for promoting retina ganglion cell axon regeneration and dendritic repair. The research of the invention finds that dasatinib has the effect of promoting RGC axon regeneration and dendritic repair after optic nerve injury. When dasatinib is adopted for treatment, repair and regeneration of retinal ganglion cell axons and dendrites after optic nerve injury can be promoted, and the purpose of treating traumatic optic nerve injury is achieved.

The present disclosure relates to means of treating ocular axis length diseases, such as myopia. The optical films of the present invention include apparatuses and methods for formulating, selecting, supplying and assembling permanent or non-permanent optical films for use with standard monochromatic eyeglasses, where the apparatuses and methods are configured with non-refractive opaque features, wherein the non-refractive opaque feature promotes an increase in the whole retinal ganglion cell activity of the wearer, which can be used as an optical signal to slow, improve, control, inhibit or reduce the speed of myopia progression in the wearer.

In some embodiments, disclosed herein are systems and methods of treating a patient that can include the steps of accessing the sphenopalatine fossa, and cannulating the inferior orbital fissure from the sphenopalatine fossa to access the retro-orbital space. The sphenopalatine fossa can be accessed via various routes, including percutaneously. Accessing the sphenopalatine fossa can include the step of inserting a needle-catheter system into the sphenopalatine fossa. Integrated needle-catheter systems as described herein can also be configured to access the trigeminal ganglion, epidural space, intrathecal space, and other desired anatomical locations.

Disclosed are compositions including a population of human enteric neural stem cells (ENSCs), wherein the population comprises at least one of a cell expressing nerve growth factor receptor (NGFR), a cell expressing integrin alpha 6 (ITGA6), a cell expressing L1 cell adhesion molecule (L1CAM), a cell that expresses proteolipid protein 1 (PLP1), and / or a cell that expresses paired-like homeobox 2B (PHOX2B), methods of producing the compositions, and their uses.

Viral constructs and methods of their use in the treatment of diseases and disorders mediated by reduced ELP1 expression are provided. The viral constructs include a coding sequence for human ELP1 under control of a heterogenous promoter (such as a small nuclear RNA promoter), allowing for an increase in ELP1 protein expression in neuron cells of the central nervous system, including for instance retinal cells. Methods of using such viral constructs to protect neural cells, for instance by reducing death of retinal ganglion cells, are also provided.

This invention discloses an injectable hydrogel for long-term sustained release of NGF and CNTF, its preparation method, and its application in visual system diseases. The bioactive factor sustained-release hydrogel of this invention comprises a hydrogel matrix and bioactive factor microspheres loaded on the matrix; the raw materials for preparing the hydrogel matrix include chitosan, type II collagen, and hyaluronic acid; the bioactive factor microspheres comprise an inner core and a capsule wall, the inner core being a bioactive factor selected from one or both of ciliary neurotrophic factor and nerve growth factor, and the capsule wall being a polylactic acid-glycolic acid copolymer. This hydrogel can achieve long-term stable release of NTF, activating endogenous neural stem cells in the retina to generate new retinal ganglion cells. It exhibits high safety, good injectability, and a long sustained-release period, and can be used to prepare drugs for treating visual system diseases such as glaucoma, optic nerve damage, and macular degeneration.

The invention provides a prevention and control film for inhibiting eye axis growth and prevention and control glasses, and belongs to the technical field of myopia prevention. The light-transmitting diaphragm comprises a light-transmitting diaphragm and circular units arranged on the surface of the light-transmitting diaphragm in an array mode, each circular unit is of a concave-convex or concave-convex structure, the thickness of the light-transmitting diaphragm ranges from 0.9 mm to 1.1 mm, the diameter of each circular unit ranges from 180 micrometers to 190 micrometers, the distance between the circle centers of every two adjacent circular units ranges from 500 micrometers to 510 micrometers, and the distance between the circle centers of every two adjacent circular units ranges from 500 micrometers to 510 micrometers. A concave-convex structure on the prevention and control film can scatter and refract incident light to form atomization distribution, the discharge frequency of M-type retinal ganglion cells can be inhibited, retinal dopamine release can be promoted, then the activity of sclera fibroblasts is affected, and ocular axis growth is delayed. According to the invention, the excessive growth of the eye axis can be inhibited, so that the effect of increasing the hyperopia reserve of children or inhibiting the development of myopia is achieved.

To provide a novel prophylactic or therapeutic for GM1 gangliosidosis, and a novel composition for preventing or treating GM1 gangliosidosis.SOLUTION: Provided is a prophylactic or therapeutic for GM1 gangliosidosis, comprising, as an active ingredient, at least one selected from the group consisting of amodiaquine, acacetin, sulfamerazine, ungerine, amiodarone, sertindole, delcorine, perphenazine, althiazide, diethylstilbestrol, thiethylperazine, harmol, skimmianine, succinylsulfathiazole, phillalbine, canavanine, harmaline, trihexyphenidyl, fluoxetine, lovastatin, haloperidol, prenylamine lactate, bromperidol, convolvamine, and miglustat, and pharmaceutically acceptable salts thereof, or solvates thereof.SELECTED DRAWING: Figure 5

The invention relates to a coherent electrical stimulation closed-loop regulation and control method and device based on neurodynamics feedback, and the method comprises simulation configuration, analogue simulation and adjustment configuration, simulates the biological parameters of a patient through the coupling of an external electric field and the driving of a calculation model, and carries out the simulation of the biological parameters of the patient through the real image data. And control parameter mapping adjustment information and phase adjustment parameter mapping relation information are obtained, so that closed-loop regulation and control of the coherent electrical stimulation on the neural rhythm are established, and mismatch possibly caused by traditional feed-forward stimulation is avoided.

The invention belongs to the technical field of biological medicines, and discloses application of quercetin in preparation of a medicine for promoting retina ganglion cell axon regeneration and dendritic repair. The research of the invention finds that quercetin has the effect of promoting RGC axon regeneration and dendritic repair after optic nerve injury. The quercetin is adopted for treatment, so that repair and regeneration of retinal ganglion cell axons and dendrites after optic nerve injury can be promoted, and the purpose of treating traumatic optic nerve injury is achieved.

Provided herein is a method of stabilizing the 9-HPT, 25-FWT, and / or FARS-neuro test score (a measure of neurologic impairment) in a human subject suffering from GM1 gangliosidosis, juvenile GM2 gangliosidosis, or sialidosis. The method comprises administering to the subject an effective amount of venglustat or a pharmaceutically acceptable salt thereof.

The present invention provides a single surgical method, procedure and / or system that creates open visual and physical access to an identified spinal treatment site that initially comprises spinal levels to be treated, wherein the spinal levels comprise at least one dorsal root ganglion. A spinal treatment procedure is performed generally in combination with implantation of a neuromodulation system that may comprise placement of electrical lead(s) on the at least one dorsal root ganglion, wherein each lead is in operative connection with a pulse generator that may also be implanted during the surgical method. Electrical stimulation may be generated with the pulse generator through the electrical leads to the at least one dorsal root ganglion during and / or after the closure of the identified spinal treatment site.

The invention provides application of BC1618 in preparation of a central nervous system protection medicine, and belongs to the technical field of medicine. As a novel drug, the BC1618 inhibits a key component subunit FBXO48 of E3 ubiquitin ligase and further stabilizes SERBP1 so as to play a nerve protection function. The research of the invention shows that the BC1618-FBXO48-SERBP1 axis can promote the survival of retinal ganglion cells and the regeneration of axons after optic nerve injury, and delay the degeneration of axons at the same time. In addition, the nerve protection function of the BC1618 can be further applied to a Parkinson's disease model. Therefore, the BC1618 can be used as a potential medicine composition for preventing or treating and controlling nervous system development disorder related diseases, and can remarkably improve the symptoms such as neuron death, axon loss, neuron dysfunction and dyskinesia caused by central nervous system injury and diseases (such as optic nerve injury and Parkinson's disease).

The application discloses a kind of circSamd4 gene knockout mouse model construction method and application.CircSamd4 gene knockout mouse animal model of the construction method of the application includes the following steps: using sgRNA to knock out the gene of circSamd4 of mouse, obtains circSamd4 gene knockout mouse.The application uses Crispr-cas9 gene knockout technology, and knocks out mouse circRNA gene circSamd4, and the obtained mouse all shows obvious glaucoma phenotype such as thinning of retina thickness, retinal ganglion cell (GCL) loss, visual function damage.Can provide simple, reliable, economic animal model for the research of glaucoma pathogenesis, drug and clinical treatment strategy screening.

The invention provides a laparoscope real-time navigation method based on augmented reality, and relates to the technical field of myoelectricity sensing, the laparoscope real-time navigation method comprises the following steps: using an impedance mapping model to output a neurodynamics coupling index by fusing an antagonistic muscle synergy contraction index, a neural rhythm multi-scale entropy, a power spectrum gravity center shift rate and an action mapping manifold degree; based on the index, through hyperbolic tangent mapping and square attenuation logic, a dynamic drift compensation gain signal and a visual information rendering density factor are generated, and adaptive adjustment of pose locking rigidity, color saturation and transparency is realized. According to the method, a visual noise reduction and physiological feedforward compensation mechanism driven by cognitive resources is constructed, model drift is effectively inhibited, and cognitive loads are reduced; in combination with index change rate-based rendering frequency adjustment and physiological signal failure switching logic, the real-time precision and robustness of the navigation system in a complex operation scene are enhanced.

There is provided a transvenous approach for accessing and targeting neural treatment sites to relieve a variety of clinical indications, including peripheral neuropathy. A neurosome approach is described that includes one or more target nerves to receive selective cryoneurolysis via a target vein. A range of different freeze and thaw cycles are performed via the target vein to induce a desired thermal treatment temperature range for selective sensory loss without adverse impact or minimal impact to associated motor nerves. The target nerves and veins are selected to combine the treatment of the identified neurosome for pain relief in addition to the regenerative properties of cryoneurolysis.

The invention relates to a nerve awakening system based on acousto-optic combination, and belongs to the technical field of neuroscience. The system comprises a multi-modal physiological sensing module, an intelligent decision-making and acousto-optic coding module, an acousto-optic joint intervention module and a closed-loop self-adaption and optimization module. The method comprises the following steps: acquiring and processing electrical activity signals of a brain nerve cluster, extracting nerve oscillation rhythm characteristics and generating standardized data; generating a target rhythm model based on the multi-scene reference rhythm library, matching a regulation and control strategy, and encoding the regulation and control strategy into an acousto-optic collaborative stimulation parameter; pre-synchronization calibration, phase locking and frequency traction are carried out on the sound waves and the light waves, and time sequence binding output is achieved; the neural electrical activity after intervention is monitored in real time, a dynamic evaluation system is constructed, and a feedback optimization mechanism is started. According to the invention, adaptive regulation and control of the nerve rhythm are realized, and the effectiveness and stability of the nerve awakening process are improved.

This invention relates to the field of biomedical technology, specifically proposing a method for preparing chiral cadmium selenide quantum dots and their application in retinal degeneration. By precisely controlling the reaction conditions, highly efficient chiral cadmium selenide quantum dots were successfully synthesized. The chiral cadmium selenide quantum dots of this invention exhibit significant protective effects against retinal damage caused by high intraocular pressure or oxidative stress, effectively improving the survival rate of retinal ganglion cells and alleviating retinal pathological changes. In a rat model, topical ocular administration demonstrated good therapeutic efficacy and biosafety. This invention provides new ideas and methods for the treatment of retinal degeneration and has broad clinical application prospects. Furthermore, the preparation method of these quantum dots and their complexes is simple and low-cost, providing new possibilities for expanding the application of quantum dots in the biomedical field.